/주식/BCTXW
BCTXW

BCTXW

USD

BriaCell Therapeutics Corp. Warrant

$0.049-0.015 (-23.721%)

실시간 가격

Healthcare
생명공학
캐나다

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$0.065

고가

$0.054

저가

$0.033

거래량

0.00M

기업 기본 정보

산업

생명공학

국가

Canada

거래 통계

거래소

NCM

통화

USD

52주 범위

저가 $0.0332현재가 $0.049고가 $0.054

관련 뉴스

GlobeNewswire

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

SITC poster to be presented on Friday, November 7, 2025, emphasizes robust anti-cancer activity of next generation Bria-OTS+ platform Lead candidates Bria-BRES+™ (breast cancer) and Bria-PROS+™ (prostate

더 보기
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models
GlobeNewswire

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitorFourth consecutive positive DSMB recommendation

더 보기
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
GlobeNewswire

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

79 clinical sites across 23 US states are currently enrolling patients in BriaCell's pivotal Phase 3 study in metastatic breast cancer (MBC) Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer

더 보기
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
GlobeNewswire

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Collaboration with MSK's Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™ for breast cancer PHILADELPHIA

더 보기
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer